Verax Research Services (Verax) announces an exciting investment opportunity with the pricing of its Initial Public Offering (“IPO”) of 8,000,000 shares.
Through its hemp research and development services, Verax Research works to ensure the safety and effectiveness of hemp products. Verax also uses its proprietary Ethnobotanical and Phytochemical database, Cannacopeia, to develop unique findings and formulations of healthcare products with hemp constituents.
Shares are available through the Dalmore Group, LLC, an investment bank in New York City (“Dalmore”) which serves as the accommodating/selling broker for the IPO. The Verax IPO share price is $6.25 per share. The minimum investment for an investor is 200 shares/ $1,250 (and multiples of $625). The offering will close not later than February 3, 2021, nine months from the date of its qualification with the SEC.
The Offering Statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on May 4, 2020 and the associated shares are qualified for sale publicly. Copies of the final Offering Circular relating to this offering may be obtained by institutional investors from:
The Verax website or the SEC’s EDGAR website.
Dalmore Group, LLC
Attn: Syndicate Department
1177 Avenue of The Americas, 7th floor
New York, NY 10036
firstname.lastname@example.org and transaction desk telephone number: 917-319-3000.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful.
About Verax Research Services, Inc.
Verax Research Services, Inc. was founded in June 2017 as a Delaware C-Corporation by proven and trusted pharmaceutical and medical device executives with a singular objective: Ensure hemp research and product development lead to safe and effective healthcare products. To accomplish this objective, Verax (Derived from Latin for “the truth”) provides research, product development, and raw material testing, as well as validation and certification of hemp constituent raw materials for Verax’s pharmaceutical and other healthcare manufacturer clients. Located in the Academic and Research facilities on the Rockville, Maryland campus of Johns Hopkins University, Verax believes it has developed the infrastructure to support our clients and to meet their hemp constituent needs. For further information about the Company, please visit the website at: VeraxResearch-IPO.com
This news release may contain forward-looking statements that reflect Verax’s current expectations regarding future events, including statements regarding the timing of and potential listing of Verax Shares on stock market exchanges, the proposed date of such offering and development and regulatory clearance of the Verax offering. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the Verax’s ongoing business, research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process and the acceptance of Verax and Verax clients’ created products by consumers as well as medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in Verax can be found in Verax’s filings with the U.S. Securities and Exchange Commission, including its Regulation A, Tier 2, Form U-1 as amended. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Verax undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise.
Inquiries to the Company should be address as below:
Verax Research Services, Inc.
James Shaver, II, Director of Investor Relations
Bureau: (888) 214-2584